EAM Investors’s Coherus Oncology CHRS Stock Holding History

EAM Investors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$524K	Buy	+309,801	New	+$550K	0.06%	261
2019 Q3	–	Sell	-66,041	Closed	-$1.46M	–	246
2019 Q2	$1.46M	Buy	+66,041	New	+$1.15M	0.36%	130
2017 Q1	–	Sell	-24,652	Closed	-$694K	–	319
2016 Q4	$694K	Sell	24,652 -13,750	-36%	-$385K	0.09%	290
2016 Q3	$1.03M	Buy	+38,402	New	+$1.05M	0.14%	249
2015 Q4	–	Sell	-35,656	Closed	-$715K	–	315
2015 Q3	$715K	Buy	+35,656	New	+$1.08M	0.11%	284
2015 Q2	–	Sell	-162,485	Closed	-$4.97M	–	327
2015 Q1	$4.97M	Buy	+162,485	New	+$4.2M	0.57%	18

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

EAM Investors's CHRS Position: Q1 2026 in Review

EAM Investors opened a new position in Coherus Oncology (CHRS) in Q1 2026: 309,801 shares worth $524K. The stake represents 0.06% of the portfolio and ranks #261 among its holdings. This is a return to the name: EAM Investors previously reported a position in CHRS as recently as Q2 2019.

EAM Investors first reported a position in CHRS in Q1 2015 and has held it in 6 quarters since. The position peaked at $4.97M in Q1 2015. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

EAM Investors held 309,801 shares of Coherus Oncology worth $524K as of Q1 2026.
Coherus Oncology was a new EAM Investors position in Q1 2026.
Coherus Oncology made up 0.06% of EAM Investors's portfolio in Q1 2026, its #261 holding.
EAM Investors first reported a position in Coherus Oncology in Q1 2015 and has held it in 6 quarters since.
EAM Investors's Coherus Oncology position peaked at $4.97M in Q1 2015.
157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.